We claim:

1. A compound of Formula (Ia):

![Chemical Structure Image](Ia)

or a pharmaceutically acceptable salt thereof.

2. The compound as claimed in claim 1, which is a compound of Formula (Ib)

![Chemical Structure Image](Ib)

or a pharmaceutically acceptable salt thereof.
3. A compound of Formula (IIa):

![Chemical Structure of IIa](image)

or a pharmaceutically acceptable salt thereof.

4. The compound as claimed in claim 3, which is a compound of Formula (IIb)

![Chemical Structure of IIb](image)

or a pharmaceutically acceptable salt thereof.

5. A parenteral formulation comprising the compound as claimed in any one of the claims 1 to 4, wherein the formulation comprises poloxamer in saline in a concentration from 1% to 10% and wherein the poloxamer is selected from poloxamer 338 or poloxamer 188.
6. A compound selected from the group consisting of:

\[ \text{[Chemical Structure]} \]

7. The parenteral formulation as claimed in claim 5, wherein the concentration of poloxamer 188 in saline is 1% to 3%.

8. The parenteral formulation as claimed in claim 7, wherein the concentration of poloxamer 188 in saline is 2%.

9. A parenteral formulation comprising the compound as claimed in any one of claims 1 to 4, wherein the formulation consists essentially of N-methyl-2-pyrrolidone.

10. A parenteral formulation comprising the compound as claimed in any one of claims 1 to 4, wherein the formulation consists essentially of dimethyl sulfoxide.

11. A parenteral formulation comprising the compound as claimed in any one of claims 1 to 4, wherein the formulation comprises 5% to 20% ethanol, 5% to 20% water, and 60% to 90% polyethylene glycol 200.

12. The parenteral formulation as claimed in claim 11, wherein the formulation comprises 10% to 15% ethanol, 10% to 15% water, and 70% to 80% polyethylene glycol 200.

13. The parenteral formulation as claimed in claim 12, wherein the formulation comprises 10% ethanol, 12% water, and 78% polyethylene glycol 200.

14. The parenteral formulation as claimed in claims 5 and 7 to 13, wherein the compound is present as a sodium salt.
15. The compound as claimed in claims 1 to 4 as and when used in preparation of a pharmaceutical composition comprising a pharmaceutically acceptable excipient, optionally along with additional therapeutic agent.

Dated this 18th day of February, 2019

Digitally signed and filed through e-filing

SACHIN BINDAL
OF K&S PARTNERS
AGENT FOR THE APPLICANT(S)
IN/PA-2560
We claim:

1. A compound of Formula (Ia):

\[ \text{(Ia)} \]

or a pharmaceutically acceptable salt thereof.

2. The compound \textit{of-as claimed in} claim 1, which is a compound of Formula (Ib)

\[ \text{(Ib)} \]

or a pharmaceutically acceptable salt thereof.

3. \textit{A pharmaceutical composition comprising a therapeutically effective amount of the compound of claim 1 or 2, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.}
4. The pharmaceutical composition of claim 3, further comprising one, two, three, or four additional therapeutic agents.

5. The pharmaceutical composition of claim 4, wherein the additional therapeutic agents are selected from the group consisting of combination drugs for HIV, other drugs for treating HIV, HIV protease inhibitors, HIV non-nucleoside or non-nucleotide inhibitors of reverse transcriptase, HIV nucleoside or nucleotide inhibitors of reverse transcriptase, HIV integrase inhibitors, HIV non-catalytic site (or allosteric) integrase inhibitors, HIV entry inhibitors, HIV maturation inhibitors, latency reversing agents, compounds that target the HIV capsid, immune-based therapies, phosphatidylinositol 3-kinase (PI3K) inhibitors, HIV antibodies, bispecific antibodies and “antibody-like” therapeutic proteins, HIV p17 matrix protein inhibitors, IL-13 antagonists, peptidyl prolyl cis-trans isomerase A inhibitors, protein disulfide isomerase inhibitors, complement C5a receptor antagonists, DNA methyltransferase inhibitor, HIV vif gene modulators, Vif dimerization antagonists, HIV-1 viral infectivity factor inhibitors, TAT protein inhibitors, HIV-1 Nef modulators, Hck tyrosine kinase modulators, mixed lineage kinase 3 (MLK 3) inhibitors, HIV-1 splicing inhibitors, Rev protein inhibitors, integrin antagonists, nucleoprotein inhibitors, splicing factor modulators, COMM domain containing protein 1 modulators, HIV ribonuclease H inhibitors, retrocyclin inhibitors, CDK-9 inhibitors, dendritic ICAM-3 grabbing nonintegrin 1 inhibitors, HIV GAG protein inhibitors, HIV POL protein inhibitors, Complement Factor H modulators, ubiquitin ligase inhibitors, deoxyribonucleotide kinase inhibitors, cyclin dependent kinase inhibitors, proprotein convertase PC9 stimulators, ATP dependent RNA helicase DDX3X inhibitors, reverse transcriptase priming complex inhibitors, G6PD and NADH oxidase inhibitors, pharmacokinetic enhancers, HIV gene therapy, and HIV vaccines, or any combinations thereof.

6. The pharmaceutical composition of claim 4, wherein the additional therapeutic agents are selected from the group consisting of HIV protease inhibiting compounds, HIV non-nucleoside inhibitors of reverse transcriptase, HIV non-nucleotide inhibitors of reverse transcriptase, HIV nucleoside inhibitors of reverse transcriptase, HIV integrase inhibitors, gp41 inhibitors, CXCR4 inhibitors, gp120 inhibitors.
inhibitors, CCR5 inhibitors, capsid polymerization inhibitors, pharmacokinetic enhancers, and other drugs for treating HIV, or any combinations thereof.

7. The pharmaceutical composition of claims 4 to 6, wherein the additional therapeutic agents are selected from the group consisting of abacavir sulfate, tenofovir, tenofovir disoproxil, tenofovir disoproxil fumarate, tenofovir disoproxil hemifumarate, tenofovir alafenamide, and tenofovir alafenamide hemifumarate.

8. The pharmaceutical composition of claims 4 to 7, wherein the additional therapeutic agents are selected from the group consisting of tenofovir alafenamide, tenofovir alafenamide fumarate and tenofovir alafenamide hemifumarate.

9. The pharmaceutical composition of claims 4 to 6, wherein the additional therapeutic agent is 4’-ethynyl-2-fluoro-2′-deoxyadenosine, bictegravir, or a pharmaceutically acceptable salt thereof.

340. A compound of Formula (IIa):

![Formula IIa](image)

or a pharmaceutically acceptable salt thereof.

444. The compound of as claimed in claim 340, which is a compound of Formula (IIb)
12. A pharmaceutical composition comprising a therapeutically effective amount of the compound of claim 10 or 11, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

13. The pharmaceutical composition of claim 12, further comprising one, two, three, or four additional therapeutic agents.

14. The pharmaceutical composition of claim 13, wherein the additional therapeutic agents are selected from the group consisting of combination drugs for HIV, other drugs for treating HIV, HIV protease inhibitors, HIV non-nucleoside or non-nucleotide inhibitors of reverse transcriptase, HIV nucleoside or nucleotide inhibitors of reverse transcriptase, HIV integrase inhibitors, HIV non-catalytic site (or allosteric) integrase inhibitors, HIV entry inhibitors, HIV maturation inhibitors, latency reversing agents, compounds that target the HIV capsid, immune-based therapies, phosphatidylinositol 3-kinase (PI3K) inhibitors, HIV antibodies, bispecific antibodies and “antibody-like” therapeutic proteins, HIV p17 matrix protein inhibitors, IL-13 antagonists, peptidyl-prolyl-cis-trans isomerase A modulators, protein disulfide isomerase inhibitors, complement C5a receptor antagonists, DNA methyltransferase inhibitor, HIV vif gene modulators, Vif dimerization antagonists, HIV-1 viral infectivity factor inhibitors, TAT protein inhibitors, HIV-1 Nef modulators, Hck tyrosine kinase modulators, mixed lineage kinase 3 (MLK 3) inhibitors, HIV-1 splicing-
inhibitors, Rev protein inhibitors, integrin antagonists, nucleoprotein inhibitors, splicing-factor modulators, COMM domain containing protein 1 modulators, HIV ribonuclease H-inhibitors, retrocyclin modulators, CDK-9 inhibitors, dendritic ICAM-3 grabbing nonintegrin-1 inhibitors, HIV GAG protein inhibitors, HIV POL protein inhibitors, Complement Factor H modulators, ubiquitin ligase inhibitors, deoxycytidine kinase inhibitors, cyclin dependent-kinase inhibitors, proprotein convertase PC9 stimulators, ATP dependent RNA helicase-DDX3X inhibitors, reverse transcriptase priming complex inhibitors, G6PD and NADH-oxidase inhibitors, pharmacokinetic enhancers, HIV gene therapy, and HIV vaccines, or any combinations thereof.

15. The pharmaceutical composition of claim 13, wherein the additional therapeutic agents are selected from the group consisting of HIV protease inhibiting compounds, HIV non-nucleoside inhibitors of reverse transcriptase, HIV non-nucleotide inhibitors of reverse transcriptase, HIV nucleoside inhibitors of reverse transcriptase, HIV integrase inhibitors, gp41 inhibitors, CXCR4 inhibitors, gp120 inhibitors, CCR5 inhibitors, capsid polymerization inhibitors, pharmacokinetic enhancers, and other drugs for treating HIV, or any combinations thereof.

16. The pharmaceutical composition of claims 13 to 15, wherein the additional therapeutic agents are selected from the group consisting of 4’-ethynyl-2-fluoro-2’-deoxyadenosine, bictegravir or a pharmaceutically acceptable salt thereof, abacavir sulfate, tenofovir, tenofovir disoproxil, tenofovir disoproxil fumarate, tenofovir disoproxil-hemifumarate, tenofovir alafenamide, and tenofovir alafenamide hemifumarate.

17. The pharmaceutical composition of claims 13 to 16, wherein the additional therapeutic agents are selected from the group consisting of 4’-ethynyl-2-fluoro-2’-deoxyadenosine, bictegravir or a pharmaceutically acceptable salt thereof, tenofovir alafenamide, tenofovir alafenamide fumarate and tenofovir alafenamide hemifumarate.

18. The pharmaceutical composition of any one of claims 3-8, 9, or 12-17, wherein the composition is a parenteral formulation.
19. The parenteral formulation according to claim 18, wherein the formulation is administered subcutaneously to a subject in need thereof.

20. The parenteral formulation according to claim 18, wherein the formulation is administered intramuscularly to a subject in need thereof.

21. The parenteral formulation of any one of claims 18-20 comprising the compound as claimed in any one of claims 1 to 4, wherein the formulation comprises poloxamer in saline in a concentration from 1% to 10% and wherein the poloxamer is selected from poloxamer 338 or poloxamer 188.

22. The parenteral formulation of any one of claims 18-21, wherein the formulation comprises a poloxamer.

23. The parenteral formulation of claim 22, wherein the poloxamer is poloxamer 338.

24. A compound selected from the group consisting of:

\[
\begin{align*}
\text{Cl} & \quad \text{NH}_2 \\
\text{O-B} & \quad \text{N-N} \\
\text{F-F} & \quad \text{F-F}
\end{align*}
\]

and

\[
\begin{align*}
\text{Cl} & \quad \text{NH}_2 \\
\text{O-B} & \quad \text{N-N} \\
\text{F} & \quad \text{F}
\end{align*}
\]

25. A compound selected from the group consisting of:

\[
\begin{align*}
\text{F} & \quad \text{F} \\
\text{F} & \quad \text{F} \\
\text{F-} & \quad \text{F-} \\
\text{N} & \quad \text{N} \\
\text{CO}_2\text{H} & \quad \text{CO}_2\text{H}
\end{align*}
\]

and

\[
\begin{align*}
\text{F} & \quad \text{F} \\
\text{F} & \quad \text{F} \\
\text{F-} & \quad \text{F-} \\
\text{N} & \quad \text{N} \\
\text{CO}_2\text{H} & \quad \text{CO}_2\text{H}
\end{align*}
\]

26. A compound of the formula:
27. — The parenteral formulation of claim 22, wherein the poloxamer is poloxamer 188.

28. — The parenteral formulation of claim 27, wherein the concentration of poloxamer 188 in saline is about 1% to about 10%.

29. — The parenteral formulation of claim 27 or 28, wherein the concentration of poloxamer 188 in saline is about 1% to about 3%.

30. — The parenteral formulation of claim 27, 28, or 29, wherein the concentration of poloxamer 188 in saline is about 2%.

31. — The parenteral formulation comprising the compound as claimed in any one of any one of claims 1 to 4, wherein the formulation comprises essentially of N-methyl-2-pyrrolidone.

32. — The parenteral formulation of any one of claims 18 to 20, wherein the formulation consists essentially of N-methyl-2-pyrrolidone.

33. — The parenteral formulation comprising the compound as claimed in any one of any one of claims 1 to 4, wherein the formulation comprises essentially of dimethyl sulfoxide.

34. — The parenteral formulation of any one of claims 18 to 20, wherein the formulation consists essentially of dimethyl sulfoxide.

35. — The parenteral formulation of any one of claims 18 to 20, wherein the formulation comprises water.
36. The parenteral formulation of any one of claims 18-20 or 35, wherein the formulation further comprises an alcohol.

37. The parenteral formulation of claim 36, wherein the alcohol is ethanol.

38. The parenteral formulation of any one of claims 18-20 or 35-37, wherein the formulation further comprises polyethylene-glycol.

39. The parenteral formulation of claim 38, wherein the polyethylene-glycol has an average molecular weight of about 200 g/mol.

40. The parenteral formulation of any one of claims 35 to 39, further comprising an inorganic base.

41. The parenteral formulation of claim 40, wherein the inorganic base is sodium hydroxide.

42. The parenteral formulation comprising the compound as claimed in any one of claims 1 to 41, and 35-41, wherein the formulation comprises about 5% to about 20% ethanol, about 5% to about 20% water, and about 60% to about 90% polyethylene glycol 200.

43. The parenteral formulation as claimed in claims 31 to 35, and 42, wherein the formulation comprises about 10% to about 15% ethanol, about 10% to about 15% water, and about 70% to about 80% polyethylene glycol 200.

44. The parenteral formulation as claimed in claims 12 to 17, and 43, wherein the formulation comprises about 10% ethanol, about 12% water, and about 78% polyethylene glycol 200.

45. The pharmaceutical composition of any one of claims 3-8, 9, or 12-17, wherein the composition is an oral formulation.
1446. The parenteral formulation as claimed in claims 5 and 7 to 13 of any one of claims 18-23 and 27-45, wherein the compound is present as a sodium salt.

15. The compound as claimed in claims 1 to 4 as and when used in preparation of a pharmaceutical composition comprising a pharmaceutically acceptable excipient, optionally along with additional therapeutic agent.